Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - New & significant data from AIPAC phase 2b trial in MBC (ASX:IMM)

* Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in th...read more

Immutep - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:IMM)

* New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmark * Constru...read more

Immutep to announce new TACTI-002 data at ASCO 2022 (ASX:IMM)

SYDNEY, AUSTRALIA – 28 April 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related i...read more

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Efti with Keytruda shows encouraging activity in lung cancer (ASX:IMM)

* All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory) * Encourag...read more

Immutep announces publication of ELCC 2022 abstract (ASX:IMM)

New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients Combination...read more

Immutep to present Phase IIb breast cancer data at ESMO 2022 (ASX:IMM)

SYDNEY, AUSTRALIA – 18 March 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new biomarker and multivariate ana...read more

Immutep - Japanese patent granted for LAG-3 antibody LAG525 (ASX:IMM)

SYDNEY, AUSTRALIA – 18 March 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 e...read more

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Application for quotation of securities (ASX:IMM)

To view the Application for quotation of +securities, download the attached PDF.

Immutep receives FDA feedback for Efti development in MBC (ASX:IMM)

SYDNEY, AUSTRALIA – 10 March 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has received constructive feed...read more

Immutep - Initial Director's Interest Notice - Lucy Turnbull (ASX:IMM)

To view the Initial Director’s Interest Notice, download the attached PDF.

Immutep - Proposed issue of securities (ASX:IMM)

To view the Proposed issue of securities, download the attached PDF.

Immutep - Appointment of Non-Executive Director (ASX:IMM)

SYDNEY, AUSTRALIA – 25 February 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the appointment of Lucy Turnbul...read more

Immutep to Present at Healthcare Investor Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – 24 February 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 relate...read more

Viewing: 181 - 195 of 200 Previous | Next